Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies

Hypertension in Pregnancy

Volumn 36, Issue 2, 2017, Pages 151-160

  Hoeller, Alice ^a   Ehrlich, Laura ^a   Golic, Michaela ^a,b   Herse, Florian ^b   Perschel, Frank H ^a   Siwetz, Monika ^c   Henrich, Wolfgang ^a   Dechend, Ralf ^b   Huppertz, Berthold ^c   Verlohren, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

intrauterine growth restriction; preeclampsia; sFlt 1 PlGF; sFlt 1; PlGF

Indexed keywords

MESSENGER RNA; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; INTRAUTERINE GROWTH RETARDATION; MATERNAL BLOOD; PLACENTA; PLACENTA DISORDER; PLACENTA TISSUE; PREECLAMPSIA; PREGNANCY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TROPHOBLAST; CASE CONTROL STUDY; COMPARATIVE STUDY; METABOLISM;

ADULT; CASE-CONTROL STUDIES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PLACENTA; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 85012096138     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.1080/10641955.2016.1273363     Document Type: Article

References (31)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R., Pre-eclampsia. Lancet 2010;376(9741):631–44.
2. Duley L., The global impact of pre-eclampsia and eclampsia. Seminars Perinatol 2009;33(3):130–7.
3. Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death:A systematic review. Lancet 2006;367(9516):1066–74.
4. Gardosi J, Kady SM, McGeown P, et al. Classification of stillbirth by relevant condition at death (ReCoDe):Population based cohort study. BMJ 2005;331(7525):1113–7.
5. Magee LA, Pels A, Helewa M, et al., Canadian Hypertensive Disorders of Pregnancy Working G. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy:Executive summary. JOGC 2014;36(5):416–41.
6. Pettit F, Mangos G, Davis G, et al. Pre-eclampsia causes adverse maternal outcomes across the gestational spectrum. Pregnancy Hypertens 2015;5(2):198–204.
7. Huppertz B., Placental origins of preeclampsia:Challenging the current hypothesis. Hypertension 2008;51(4):970–5.
8. Redman CW, Sargent IL., Latest advances in understanding preeclampsia. Science 2005;308(5728):1592–4.
9. De Falco S., The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012;44(1):1–9.
10. Holmes K, Roberts OL, Thomas AM, Cross MJ., Vascular endothelial growth factor receptor-2:Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19(10):2003–12.
11. Kendall RL, Thomas KA., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993;90(22):10705–9.
12. Lu F, Longo M, Tamayo E, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007;196(4):396 e1–7; discussion e7.
13. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111(5):649–58.
14. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206(1):58e1–8.
15. Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci 2007;112(1):51–7.
16. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125(7):911–9.
17. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy:Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20(1):IX–XIV.
18. Turan S, Miller J, Baschat AA., Integrated testing and management in fetal growth restriction. Semin Perinat 2008;32(3):194–200.
19. Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013;61(5):932–42.
20. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor:Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188(1):177–82.
21. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia:A prospective multicenter study. Circulation 2013;128(19):2121–31.
22. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004;350(7):672–83.
23. Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates:Relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90(8):4895–903.
24. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients:pathophysiological consequences. J Clin Endocrinol Metab 2003;88(11):5555–63.
25. Kumazaki K, Nakayama M, Suehara N, Wada Y., Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions. Human Pathol 2002;33(11):1069–77.
26. Foidart JM, Schaaps JP, Chantraine F, et al. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia:A step forward but not the definitive answer. J Reprod Immunol 2009;82(2):106–11.
27. Schlembach D, Wallner W, Sengenberger R, et al. Angiogenic growth factor levels in maternal and fetal blood:Correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007;29(4):407–13.
28. Huppertz B., Maternal-fetal interactions, predictive markers for preeclampsia, and programming. J Reprod Immunol 2015;108:26–32.
29. Helske S, Vuorela P, Carpen O, et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Human Reprod 2001;7(2):205–10.
30. Chung JY, Song Y, Wang Y, et al. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2004;89(5):2484–90.
31. Nevo O, Many A, Xu J, et al. Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2008;93(1):285–92.